What does proceeds from sale of priority review voucher mean?

Reflects cash inflows generated from the sale of regulatory priority review vouchers granted by health authorities for developing treatments for rare diseases. This represents a non-recurring, opportunistic source of capital that monetizes regulatory assets.

PTC Therapeutics PTCT Proceeds From Sale Of Priority Review Voucher

Proceeds From Sale Of Priority Review Voucher at other companies

RenaissanceRe HoldingsRNR

$3M-88.2%

Columbia Banking SystemsCOLB

$72M+38.5%

Cadence Design SystemsCDNS

$40.44M+3,146%

Ionis PharmaceuticalsIONS

$0—

ViatrisVTRS

$1.6M—

Motorola Solutions, Inc.MSI

$2M-80.0%

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept ptct:ProceedsFromSaleOfPriorityReviewVoucher.

The official record: PTC Therapeutics’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's proceeds from sale of priority review voucher.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's proceeds from sale of priority review voucher?: PTC Therapeutics (PTCT) reported proceeds from sale of priority review voucher of $37.5M in Q4 2024.
What does proceeds from sale of priority review voucher mean?: Reflects cash inflows generated from the sale of regulatory priority review vouchers granted by health authorities for developing treatments for rare diseases. This represents a non-recurring, opportunistic source of capital that monetizes regulatory assets.